CD274 and laryngotracheoesophageal cleft: Our results, demonstrating significant improvements in ORR and DCR with Tislelizumab, are consistent with the established efficacy profile of PD-1/PD-L1 blockade in LC, as evidenced by numerous meta-analyses for other agents.